Bristol Myers Deal Sweetener Tumbles on FDA Delay Jitters

(Bloomberg) -- The all-or-nothing payout that Bristol Myers Squibb Co. used to sweeten its purchase of Celgene Corp. is on track for its worst day ever as investors weighed the impact of the corona...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.